publication . Article . 2013

Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo.

Saint-Aubert, L.; Nemmi, F.; Péran, P.; Barbeau, E. J.; Payoux, P.; Chollet, F.; Pariente, J.;
Open Access English
  • Published: 01 Jan 2013
  • Publisher: HAL CCSD
Purpose Florbetapir (AV-45) has been shown to be a reliable tool for assessing in vivo amyloid load in patients with Alzheimer’s disease from the early stages. However, nonspecific white matter binding has been reported in healthy subjects as well as in patients with Alzheimer’s disease. To avoid this issue, cortical quantification might increase the reliability of AV-45 PET analyses. In this study, we compared two quantification methods for AV-45 binding, a classical method relying on PET template registration (route 1), and a MRI-based method (route 2) for cortical quantification. Methods We recruited 22 patients at the prodromal stage of Alzheimer’s disease a...
free text keywords: [SCCO.NEUR]Cognitive science/Neuroscience, Radiology Nuclear Medicine and imaging, Original Article, Alzheimer’s disease, Florbetapir, Amyloid, PET imaging, Cortex, General Medicine, Nuclear medicine, business.industry, business, In vivo, Positron emission tomography, medicine.diagnostic_test, medicine, Pathology, medicine.medical_specialty, Magnetic resonance imaging, Alzheimer's disease, medicine.disease, White matter, medicine.anatomical_structure
31 references, page 1 of 3

McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34: 939-944 [OpenAIRE] [PubMed] [DOI]

McKhann, GM, Knopman, DS, Chertkow, H, Hyman, BT, Jack, CR, Kawas, CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 263-269 [OpenAIRE] [PubMed] [DOI]

Dubois, B, Feldman, HH, Jacova, C, Dekosky, ST, Barberger-Gateau, P, Cummings, J. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6: 734-746 [PubMed] [DOI]

Klunk, WE, Engler, H, Nordberg, A, Wang, Y, Blomqvist, G, Holt, DP. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55: 306-319 [OpenAIRE] [PubMed] [DOI]

Clark, CM, Schneider, JA, Bedell, BJ, Beach, TG, Bilker, WB, Mintun, MA. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305: 275-283 [OpenAIRE] [PubMed] [DOI]

Jack, CR, Lowe, VJ, Senjem, ML, Weigand, SD, Kemp, BJ, Shiung, MM. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008; 131: 665-680 [OpenAIRE] [PubMed] [DOI]

Tosun, D, Schuff, N, Mathis, CA, Jagust, W, Weiner, MW. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain. 2011; 134: 1077-1088 [OpenAIRE] [PubMed] [DOI]

Fleisher, AS, Chen, K, Liu, X, Roontiva, A, Thiyyagura, P, Ayutyanont, N. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011; 68: 1404-1411 [OpenAIRE] [PubMed] [DOI]

Wong, DF, Rosenberg, PB, Zhou, Y, Kumar, A, Raymont, V, Ravert, HT. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010; 51: 913-920 [OpenAIRE] [PubMed] [DOI]

Rowe, CC, Ellis, KA, Rimajova, M, Bourgeat, P, Pike, KE, Jones, G. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010; 31: 1275-1283 [OpenAIRE] [PubMed] [DOI]

Johnson, KA, Sperling, RA, Gidicsin, CM, Carmasin, JS, Maye, JE, Coleman, RE. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013; 9 (5 Suppl): S72-S83 [OpenAIRE] [PubMed] [DOI]

Saint-Aubert, L, Barbeau, EJ, Peran, P, Nemmi, F, Vervueren, C, Mirabel, H. Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients. EJNMMI Res. 2013; 3: 43 [OpenAIRE] [PubMed] [DOI]

Saint-Aubert, L, Planton, M, Hannequin, D, Albucher, JF, Delisle, MB, Payoux, P. Amyloid imaging with AV45 ((18)F-florbetapir) in a cognitively normal AbetaPP duplication carrier. J Alzheimers Dis. 2012; 28: 877-883 [PubMed]

14.FDA approves 18F-florbetapir PET agent. J Nucl Med. 2012;53:15N. doi:53/6/15N [pii]

Booij, J, Arbizu, J, Darcourt, J, Hesse, S, Nobili, F, Payoux, P. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013; 40: 1122-1125 [OpenAIRE] [PubMed] [DOI]

31 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2013

Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo.

Saint-Aubert, L.; Nemmi, F.; Péran, P.; Barbeau, E. J.; Payoux, P.; Chollet, F.; Pariente, J.;